Volume 18, Issue 3 194075 pp. 129-136
Article
Open Access

Surfactant Protein B Intron 4 Variation in German Patients with COPD and Acute Respiratory Failure

Carola Seifart

Carola Seifart

Department of Internal Medicine Division Respiratory and Critical Care Medicine Philipps-University of Marburg 35043 Marburg, Germany

Search for more papers by this author
Alexandra Plagens

Alexandra Plagens

Department of Internal Medicine Division Respiratory and Critical Care Medicine Philipps-University of Marburg 35043 Marburg, Germany

Search for more papers by this author
Dörte Brödje

Dörte Brödje

Department of Internal Medicine Division Respiratory and Critical Care Medicine Philipps-University of Marburg 35043 Marburg, Germany

Search for more papers by this author
Bernd Müller

Bernd Müller

Department of Internal Medicine Division Respiratory and Critical Care Medicine Philipps-University of Marburg 35043 Marburg, Germany

Search for more papers by this author
Peter von Wichert

Peter von Wichert

Department of Internal Medicine Division Respiratory and Critical Care Medicine Philipps-University of Marburg 35043 Marburg, Germany

Search for more papers by this author
Joanna Floros

Joanna Floros

Departments of Cellular and Molecular Physiology and Pediatrics Pennsylvania State University College of Medicine P.O. Box 850 500 University Dr. Hershey PA 17033, USA

Search for more papers by this author
First published: 12 June 2013
Citations: 28

Abstract

Chronic obstructive pulmonary disease (COPD) is a major health problem. Genetic factors that contribute to the disease have been postulated. The pulmonary surfactant protein B (SP-B), which is essential for normal lung function, is considered as a candidate gene for COPD in this case-control study. We studied the SP-B intron 4 size variants in 346 individuals. This group consisted of 118 patients with chronic bronchitis or COPD, including 24 patients with acute respiratory failure (ARF) in COPD, 118 matched controls without pulmonary disease and 110 healthy individuals (population control). The frequency of intron 4 variants was similar in either control group (10.9%, 14.4% respectively), with a small increase in the COPD group (18.6%). This increase was due to a high increase of intron 4 variants in the ARF subgroup (37.5%, p = 0.003, OR 4.9, 95% CI: 1.76–13.6). The data indicate that SP-B intron 4 variants may associate with increased risk of ARF in COPD and may be used as a marker of susceptibility in this disease subgroup.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.